BAY79-4620

DRUG2 trials

Sponsors

Bayer

Conditions

Neoplasms

Phase 1

To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors

CompletedNCT01028755

Start: 2009-11-30End: 2013-04-30Updated: 2015-01-21

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors

TerminatedNCT01065623

Start: 2010-04-30End: 2010-08-31Updated: 2014-10-01